2 Stem cellsIntroduction; Stem cell definitions and distinctions; Hematopoietic stem cell concepts and their origin; The cellular compartment model; Models of lineage commitment; Molecular regulation of hematopoiesis; Cell-intrinsic regulators of hematopoiesis; Cell-extrinsic regulators; Components of the hematopoietic microenvironmental niche; Trafficking of primitive hematopoietic cells; Hematopoietic ontogeny; Homing and engraftment of HSCs following infusion; Egress of HSCs from bone marrow under physiological conditions; Manipulating HSCs for clinical use; Mobilization of HSCs
Isolating stem cells for manipulationSummary; Further reading; 3 The genetics of acute myeloid leukemias; Introduction; AML with recurrent cytogenetic abnormalities; Core-binding factor leukemias; Acute promyelocytic leukemia; KMT2A gene rearrangements (11q23); Other rare chromosomal translocations; Numerical chromosomal abnormalities; Molecular genetic aberrations not detectable by conventional cytogenetics; Driver gene mutations; Activated signaling; Myeloid transcription factors; Tumor suppressors; Spliceosome genes; Cohesin complex genes; DNA methylation; Chromatin modifiers
AML therapies and MRD monitoring targeted by geneticsSummary; Further reading; 4 Molecular diagnostics and risk assessment in myeloid malignancies; Introduction; Clonal hematopoiesis; Myelodysplastic syndromes; Acute myeloid leukemia; General methodology of cytogenetic analysis in hematological malignancies; Methods of detection; Genetic and clinical consequences of chromosomal translocation; Karyotypic evolution; Clinical implications; Treatment selection; Recurrent cytogenetic abnormalities in MDS; Recurrent cytogenetic aberrations in AML
Notes
Therapy-related chromosomal aberrations in secondary AML
